These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29669928)

  • 1. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
    Yan Y; Cao S; Liu X; Harrington SM; Bindeman WE; Adjei AA; Jang JS; Jen J; Li Y; Chanana P; Mansfield AS; Park SS; Markovic SN; Dronca RS; Dong H
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment.
    Yamauchi T; Hoki T; Oba T; Saito H; Attwood K; Sabel MS; Chang AE; Odunsi K; Ito F
    JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32255766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and Prognostic Implications of Circulating CX3CR1
    Abdelfatah E; Long MD; Kajihara R; Oba T; Yamauchi T; Chen H; Sarkar J; Attwood K; Matsuzaki J; Segal BH; Dy GK; Ito F
    Cancer Res Commun; 2023 Mar; 3(3):510-520. PubMed ID: 37009132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
    Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD103
    Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
    Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
    [No Abstract]   [Full Text] [Related]  

  • 8. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation, Transcriptomic States, and Clinical Relevance of CX3CR1+ CD8 T Cells in Melanoma.
    Ishigaki H; Yamauchi T; Long MD; Hoki T; Yamamoto Y; Oba T; Ito F
    Cancer Res Commun; 2024 Jul; 4(7):1802-1814. PubMed ID: 38881188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased PD-1
    Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral CX3CR1
    Li C; Zhang Z; Cai Q; Zhao Q; Wu H; Li J; Liu Y; Zhao X; Liu J; Ping Y; Shan J; Yang S; Zhang Y
    Oncoimmunology; 2024; 13(1):2355684. PubMed ID: 38798746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients.
    Combadière B; Faure S; Autran B; Debré P; Combadière C
    AIDS; 2003 Jun; 17(9):1279-90. PubMed ID: 12799549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
    Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
    J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors.
    Yamauchi T; Hoki T; Oba T; Jain V; Chen H; Attwood K; Battaglia S; George S; Chatta G; Puzanov I; Morrison C; Odunsi K; Segal BH; Dy GK; Ernstoff MS; Ito F
    Nat Commun; 2021 Mar; 12(1):1402. PubMed ID: 33658501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
    Vera Aguilera J; Paludo J; McWilliams RR; Zhang H; Li Y; Kumar AB; Failing J; Kottschade LA; Block MS; Markovic SN; Dong H; Dronca RS; Yan Y
    Melanoma Res; 2020 Aug; 30(4):364-375. PubMed ID: 32404734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.